Amarin reported $573.06M in Current Assets for its fiscal quarter ending in March of 2025.


Current Assets Change Date
AbbVie USD 27.68B 2.09B Mar/2025
Alnylam Pharmaceuticals USD 3.64B 375.44M Jun/2025
Amarin USD 573.06M 22.34M Mar/2025
AstraZeneca USD 28.94B 2.8B Jun/2025
DBV Technologies USD 121.24M 92.09M Jun/2025
GlaxoSmithKline GBP 17.67B 412M Jun/2025
Halozyme Therapeutics USD 1.12B 139.35M Jun/2025
Ionis Pharmaceuticals USD 2.58B 158.22M Jun/2025
Neurocrine Biosciences USD 1.75B 111M Jun/2025
Novartis USD 25.94B 831M Jun/2025